Xilio Therapeutics, Inc. (XLO) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
XLO Revenue Growth
XLO Revenue Analysis (2019–2025)
As of May 8, 2026, Xilio Therapeutics, Inc. (XLO) generated trailing twelve-month (TTM) revenue of $43.8 million, reflecting explosive growth of +693.9% year-over-year. The most recent quarter (Q4 2025) recorded $13.7 million in revenue, down 28.2% sequentially.
Looking at the longer-term picture, XLO's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $43.8 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), AGEN (+10.4% YoY), and CLDX (-78.6% YoY), XLO has outperformed the peer group in terms of revenue growth. Compare XLO vs RCUS →
XLO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XLOCurrent | $44M | +693.9% | - | -95.9% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 CLDX | $2M | -78.6% | -27.4% | -19160.0% |
XLO Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $43.8M | +589.9% | $0 | - | $-41,982,000 | -95.9% |
| 2024 | $6.3M | - | $6.3M | 100.0% | $-60,582,000 | -954.9% |
| 2023 | $0 | - | $0 | - | $-79,133,000 | - |
| 2022 | $0 | - | $0 | - | $-89,149,000 | - |
| 2021 | $0 | - | $-1,499,000 | - | $-75,044,000 | - |
| 2020 | $0 | - | $-1,065,000 | - | $-54,563,000 | - |
| 2019 | $0 | - | $-240,000 | - | $-19,027,000 | - |
See XLO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XLO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XLO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXLO — Frequently Asked Questions
Quick answers to the most common questions about buying XLO stock.
Is XLO's revenue growth accelerating or slowing?
XLO revenue is accelerating at +693.9% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $44M. Growth momentum has increased versus prior periods.
What is XLO's long-term revenue growth rate?
Xilio Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +693.9% is above this long-term average.
How is XLO's revenue distributed by segment?
XLO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.